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AbstrACt
Introduction 24-hour ambulatory blood pressure 
monitoring (ABPM) is the gold standard diagnostic method 
for hypertension, but has some shortcomings in clinical 
practice while clinical settings often lack sufficient devices 
to accommodate all patients with suspected hypertension. 
Home blood pressure monitoring (HBPM) and office blood 
pressure monitoring (OBPM) also have shortcomings, such 
as the white coat effect or a lack of accuracy. This study 
aims to study the validity of a new method of diagnosing 
hypertension consisting of monitoring blood pressure (BP) 
for 1 hour and comparing it with OBPM and HBPM and 
examining the sensitivity and specificity of this method 
compared with 24-hour ABPM. The patient experience will 
be examined in each method. 
Methods and analysis A minimum sample of 214 patients 
requiring a diagnostic test for hypertension from three urban 
primary healthcare centres will be included. Participants will 
undergo 24-hour ABPM, 1-hour BP measurement (1-BPM), 
OBPM for three consecutive weeks and HBPM. Patients will 
follow a random sequence to first receive 24-hour ABPM 
or 1-hour ABPM. Daytime 24-hour ABPM records will be 
compared with the other monitoring methods using the 
correlation coefficient and Bland Altman plots. The kappa 
concordance index and the sensitivity and specificity of the 
methods will be calculated. The patient’s experience will be 
studied, with selected indicators of efficiency and satisfaction 
calculated using parametric tests.
Ethics and dissemination The protocol has been 
authorised by the research ethics committee of the 
Hospital Clinic of Barcelona (Ref. HCB/2014/0615): 
protocol details and amendments will be recorded 
and reported to  ClinicalTrials. com. The results will be 
disseminated in peer-reviewed literature, and to policy 
makers and healthcare partners.
trial registration NCT03147573; Pre-results.
bACkground
Hypertension, a leading cardiovascular risk 
factor that causes premature morbidity and 
mortality, is associated with an increased risk 
of cerebrovascular disease (haemorrhagic 
or ischaemic), coronary heart disease, heart 
failure, chronic renal failure, peripheral 
vascular disease, cognitive impairment and 
premature death.1 2 In high-income coun-
tries, the age-standardised prevalence of 
hypertension rises to 28.5% (95% CI 27.3% 
to 29.7%).3 
Current evidence suggests that patients 
with systolic blood pressure (SBP) ≥140 mm 
Hg and/or diastolic blood pressure (DBP) 
≥90 mm Hg require treatment to reduce the 
risk of cardiovascular and kidney disease.4 
However, not all patients with these values 
have a high cardiovascular risk, sometimes 
due to factors such as white coat hypertension. 
The diagnosis of hypertension requires accu-
rate blood pressure (BP) monitoring to deter-
mine whether the patient has constant high 
BP values and this requires various determi-
nations. At present, clinical guidelines accept 
three methods of BP monitoring: 24-hour 
ambulatory BP monitoring (24-hour ABPM), 
home BP monitoring (HBPM) and office BP 
monitoring (OBPM).4–6
24-hour ABPM, the gold standard, consists 
of applying an automatic oscillometer sphyg-
momanometer connected to a cuff on the 
patient's arm. The device records BP values 
strengths and limitations
 ► This trial will examine whether the sensitivity and 
specificity of 1-hour blood pressure (BP) monitoring 
is comparable with 24 hours monitoring and other 
conventional methods of diagnosing hypertension.
 ► Validation of the new method would not allow night-
time recording of BP and does not seek to substitute 
24 hours monitoring.
 ► This study will examine the patient experience of the 
new BP monitoring methods studied.
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for 20 or 30 min during 24 hours.4 This identifies differ-
ences between day and night and the risk associated with 
hypertension.7 8 However, the high incidence of hyper-
tension means it cannot be carried out in all patients who 
require it, and 24-hour ABPM is not always available for 
all primary healthcare patients and is uncomfortable.9
HBPM measures BP at home or in the pharmacy. 
Determinations may be made by patients or relatives after 
receiving instruction.10 This method avoids bias due to 
the white coat effect. However, the benefits may be lost 
due to incorrect application of the technique or a lack of 
standardisation of the measuring equipment (measure-
ment with a mercury sphygmomanometer is still used).11
OBPM consists of taking the BP measures at the clinic for 
several days. After determining the reference arm, three 
determinations are made once a week for three consecu-
tive weeks and the mean of these determinations is calcu-
lated. The disadvantages of OBPM are the overdiagnosis 
of hypertension, unnecessary treatments in 15%–30% of 
patients,8 the inability to detect sudden changes in BP, 
measurement errors, the limited number of records that 
can be made, and the risk of confusing isolated hyperten-
sion, the white coat effect and the lack of correlation with 
real BP.12 13 Other drawbacks are the lack of data on the 
prognostic value and the definition.7 14 15 However, despite 
its disadvantages, clinicians often perceive that OBPM is 
controllable and verifiable, and therefore it persists as the 
preferred method, including in large population studies 
and pharmacological clinical trials with a required diag-
nosis of hypertension.12 16
Recently, two studies have examined the effectiveness 
of two new methods which use a modified 24-hour ABPM 
device. One takes a set of measurements during 30 min 
and the other during 60 min.17 18 These methods have 
some of the advantages of OBPM: the clinician can 
verify and control the process because the patient is in 
the clinic but avoiding the frequent white coat effect. 
In 1 hour-BP measurement (1-BPM), mean daytime BP 
values were similar to 24-hour ABPM, with a sensitivity of 
85.2% (95% CI 67.5% to 94.1%) and a specificity of 92% 
(95% CI 83.6% to 96.3%) for masked white coat hyper-
tension.18 However, 1-BPM requires further study for use 
in clinical practice, and the patient experience in terms 
of handling, satisfaction, understanding and adherence is 
unclear. Patient involvement in the evaluation is required 
to improve the quality of care, and to increase effective-
ness and the patient’s sensitivity to their health status 
according to their perceived needs.19 However, this has 
not been widely reported in previous studies and current 
BP monitoring methods have not been studied in the 
light of patient experience.13
The European, North American and British guide-
lines recommend the diagnosis should be made after 
verifying BP values with an ambulatory method involving 
various measurements or, at best, using 24-hour ABPM.4–6 
However, all methods of measuring hypertension in daily 
clinical practice have shown important shortcomings 
related to the accuracy of monitoring, and 24-hour ABPM 
is not feasible in all cases.9 The aim of this study is to 
examine the accuracy of the 1-BPM method against the 
out-of-office and office methods, taking 24-hour ABPM as 
the gold standard.
MEthods/dEsIgn
study objectives
To study the validity (sensitivity and specificity) of 
1-BPM versus OBPM in three visits and HBPM, using 
24-hour ABPM as the reference during the daytime 
period, and to examine patient acceptance and experi-
ence of the methods and compare the cost of 1-BPM with 
the other methods.
design
This study protocol presents a diagnostic accuracy study 
of BP measurement using ABPM. Patients requiring a 
diagnostic test for high BP will be prospectively included. 
All participants will undergo 24-hour ABPM. The speci-
ficity and sensibility will be studied with respect to 1-BPM, 
HBPM and OBPM at three visits. The trial registration 
identifier in  ClinicalTrials. gov web is CT03147573, regis-
tered 10 May 2017.
study population
Patients assigned to a primary healthcare centre 
(PHC) referred for a diagnostic test for hypertension by 
the family physician.
Inclusion and exclusion criteria
Inclusion criteria will be as follows: (1) age ≥18 years, (2) 
patients seen routinely in the study PHCs, (3) voluntary 
participation and (4) family physician referral for diag-
nosis of high BP. Exclusion criteria will be as follows: 
(1) severe physical or cognitive limitations, (2) previous 
episodes of arrhythmia, atrial fibrillation with rapid 
ventricular response, frequent ventricular extra-systole or 
other arrhythmias, (3) Parkinson’s disease or any other 
condition causing permanent tremor, (4) arm circum-
ference >42 cm, (5) arterial-venous fistula in the arm, 
(6) mental disorders or intolerance to BP measurement 
method, (7) inability to attend the study PHC and (8) 
programmed hospitalisation during the study period.
Clinical setting
Participants will be recruited from three urban PHCs 
located in Barcelona (Spain), which include 54 family 
physicians and 56 community nurses who serve 95 185 
patients. In 2017, 65.21% of patients were seen ≥1 time. 
Participant inclusion commenced in June 2017, and the 
estimated completion date is June 2019.
outcome measurements
Primary outcome
Diagnosis of hypertension, according to The European 
Society of Cardiology and The European Society of 
Hypertension (ESC/ESH) Arterial Hypertension guide-
lines definitions4 (excluding 1-BPM):
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 ► 24-hour ABPM: daytime mean of ≥135 mm Hg SBP 
and/or≥85 mm Hg DBP.
 ► OBPM: mean of three visits≥140 mm Hg and/or DBP) 
≥90 mm Hg.
 ► HBPM: mean of ≥135 mm Hg SBP and/or≥85 mm Hg 
DBP.
 ► 1-BPM: mean of ≥135 mm Hg SBP and/or≥85 mm Hg 
DBP.
Patient experience
Satisfaction with the time necessary to obtain the test 
result, time required by the patient to obtain the result 
(including time of travel to the centre), comfort of the test 
and opinion about recommending it to another patient. 
These variables will be collected using visual analogic 
scales (online supplementary file 1); nurse collaborators 
will assist participants if required.
Cost
Cost of the visit, number of visits needed to carry out 
the diagnostic procedure, any spending reported by the 
participant, cost of travel to the health centre (if appli-
cable) and other reported expenses.
other variables
Sociodemographic: age and sex, educational level, social 
class; clinical variables: weight, height and body mass 
index, abdominal perimeter, ECG, cardiovascular risk 
factors, smoking, alcohol consumption, level of physical 
activity, diabetes mellitus, dyslipidaemia, obesity, previous 
prescription of antihypertensive medication and type.
bP measurement methods
24-hour ABPM
BP measurement will be made using Oscar 2, model 250, 
24-hour ABPM, Suntech Medical, which is approved by 
the US Food and Drug Administration.20 Using a stan-
dard cuff adapted to the arm, the device is activated at 
intervals for 24 hours: every 20 min during the daytime 
and every 30 min during night-time. A minimum of 70% 
of BP records are needed for a valid ABPM measurement. 
The device stores the BP records in an internal memory 
that is downloaded once the test finishes the next day. 
The characteristics are shown elsewhere.21
1-BPM
Measurement of BP for 1 hour using the 24-hour ABPM 
device. BP will be measured every 5 min. During the hour, 
the patient will remain in a quiet room in the primary 
healthcare centre, without walking actively, eating or 
smoking. After 1 hour, the device and arm cuff will be 
removed.
OBPM
A standard device will be used (Omron m6 AC, Japan). 
The patient must not have smoked tobacco, drunk coffee 
or other caffeine-containing drinks in the previous 30 min 
or had a large meal in the previous 2 hours, complain of 
pain or anxiety and must not have psychomotor agitation. 
The patient will be seated with their arms crossed, the 
legs uncrossed and the feet touching the floor. DBP and 
SBP will be determined in the two arms, and the arm with 
the highest BP will be selected; if both are equal either 
will be chosen. After 5 min, a new determination will be 
made, which will be the one recorded in the data collec-
tion notebook. In following visits, BP will be determined 
following the same procedure but only in the reference 
arm.
HBPM
HBPM will be carried out according to daily clinical 
practice. All participants will be asked to provide at least 
three BP measurements over 3 days. Nurses will check 
whether the participant has an adequate BP monitor 
(a semiautomatic, validated BP monitor); if they do not 
have access to a validated BP device at home, they will be 
asked to measure the BP in the pharmacy. Participants 
will receive instructions and an information sheet on the 
BP measuring method. BP should be measured in a quiet 
room without noise or interruptions. Patients should 
be relaxed and should not drink, eat, smoke or exer-
cise during the previous half hour. Patients should not 
talk during the measurement and should rest for 5 min 
beforehand. They should sit comfortably with the back 
resting on the back of the chair, with the legs uncrossed 
and arms not constrained by clothing. The cuff should 
be placed on the arm, 2 or 3 cm above the elbow, leaving 
the hand on the back and the elbow slightly flexed at the 
height of the heart. Two measurements will be made at 
least 2 min apart and the mean of the two will be used. 
Measurement in the pharmacy will follow the recom-
mendations of pharmacy employees, as in usual practice. 
Table 1 summarises the number of days/hours/visits 
needed, measurements obtained and the threshold used 
to diagnose hypertension in each of the four methods.
study procedures
The study will have a total of three visits. Figure 1 presents 
an overview of the tasks carried out at each study visit and 
a flowchart of the process. The tasks are shown below.
Visit 0
Patients with inclusion criteria seen by PHC physicians or 
nurses will be invited to participate. If the potential partic-
ipant shows interest, they will receive information on the 
study requirements. Any patient doubts will be answered 
and clinicians will offer a brochure with detailed infor-
mation on the study. At this visit, the nurse will measure 
the BP and determine the reference arm, will measure 
the first OBPM and will request a HBPM. The next day, 
the nurse will call the patient to confirm inclusion and 
arrange the next visit.
Visit 1
Between 5 and 7 days after visit 0, the participant will 
attend visit 1 with the nurse. All nurses will be instructed 
by the study coordinator in data collection and the study 
procedures. Before starting the procedures, they will 
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review the study aims and the patient will be asked to sign 
an informed consent. Thereafter, the nurse will record 
anthropometric variables and carry out the second deter-
mination of OBPM and patients will follow the 1-BPM 
or 24-hour ABPM according a randomisation sequence. 
If 24-hour ABPM is chosen, a visit will be arranged from 
Monday to Thursday (not Friday because the device must 
be removed the next day at the same time).
At the end of this visit, an electrocardiographic record 
will be made. A new HBPM will be requested.
Visit 2
Between 5 and 7 days after visit 1, the third OBPM deter-
mination will be made. 1-BPM will be administered to 
patients who underwent 24-hour ABPM during visit 2 and 
1-BPM in patients in whom 24-hour ABPM was carried out 
during visit 1. The nurse will collect data on the variables 
concerning the patient's experience of the four methods 
using the patient experience sheet (online supplemen-
tary appendix 1). The nurse will record the HBPM partici-
pants have provided. After completion, the patient will be 
referred to their general practitioner to assess the results.
Participant discontinuation
Participants who start any drug treatment to treat hyper-
tension before visit 2, or do not attend any of the visits for 
three consecutive weeks will be withdrawn from the study. 
To promote retention, the nurse will phone participants 
before the visit and will change the date of the visit to 
another day of the same week if the participant requests.
1-BPM and 24-hour ABPM sequence randomisation
As 1-BPM and 24-hour ABPM use the same device, there 
might be some adaptation effect, which will be mitigated 
by randomisation: at visit 1 and visit 2, each participant 
will be allocated randomly to 1-BPM or 24-hour ABPM. 
Table 1 Summary of the methods according the time required, the number of measurements of BP and the threshold of BP to 
diagnose hypertension
Method
Number of days/hours/visits 
needed
Number measurements 
obtained Hypertension threshold
24-hour ABPM: 
daytime 
24 hours 49 to 52 ≥135 mm Hg SBP and/or ≥85  mm Hg DBP
OBPM Three consultations: once a week 
in three consecutive weeks
3 ≥140 mm Hg SBP and/or ≥90 mm Hg DBP
HBPM Two consultations 3 ≥135 mm Hg SBP and/or ≥85  mm Hg DBP
1-BPM One visit of 1  hour 13 ≥135 mm Hg SBP and/or ≥85  mm Hg DBP
1-BPM, 1-hour blood pressure monitoring; ABPM, ambulatory  blood pressure monitoring; BP, blood pressure; DBP, diastolic BP; 
HBPM, home BP monitoring; OBPM, office BP monitoring; SBP, systolic BP.
Figure 1 Research visits and content of study assessments (left) and flow chart of study design (right). 1-BPM, 1-hour 
ambulatory blood pressure monitoring; 24-hour ABPM, 24-hour ambulatory blood pressure monitoring; HBPM, home blood 
pressure monitoring; OBPM, office blood pressure monitoring.
 o
n
 9 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029268 on 27 May 2019. Downloaded from 
5González-de Paz L, et al. BMJ Open 2019;9:e029268. doi:10.1136/bmjopen-2019-029268
Open access
The randomisation sequence will be generated previously 
and will not be changed. We do not foresee that any other 
randomisation method will be needed to examine the 
study outcomes.
statistical analysis
Categorical variables will be presented as absolute 
frequency and percentages and continuous variables as 
mean and SD, or median and IQR. The Shapiro-Wilk 
normality test will be used to check the normal distribu-
tion of variables. Pearson’s correlation coefficient will be 
calculated for 1-BPM, HBPM and OBPM. The Bland-Al-
tman method will be applied with the graphic represen-
tation of the correlations of the intervals (the differences 
between the measurements against the mean) to confirm 
independence between the differences obtained with 
each method and the magnitude. The prevalence of white 
coat hypertension and masked hypertension will be calcu-
lated. The proportion of well-classified participants with 
1-BPM will be estimated with respect to 24-hour ABPM 
and HBPM and OBPM, and the kappa index will be calcu-
lated to measure the degree of agreement between the 
four methods, to classify the participants in subpopula-
tions of hypertensive patients. Sensitivity, specificity and 
positive and negative predictive values will be calculated 
for the diagnosis of hypertension subtypes. All concor-
dance and correlation results will be based on the means 
of SBP and DBP readings. To analyse the cost, the mean 
of the sum of all the cost variables will be analysed and 
each variable will be analysed separately by calculating 
the differences between means by analysis of variance. 
Likewise, the time necessary to obtain the result of the 
test and the validity with respect to 24-hour ABPM will be 
analysed. Values of p<0.05 will be considered statistically 
significant. The statistical analysis will be made using the 
R V.3 for Windows statistical program.
sample size calculation
A recent study comparing 1-BPM with 24-hour ABPM 
found that 1-BPM classified 87.3% of patients correctly. 
To achieve a precision of 5% in the estimate of a propor-
tion with 95% CIs, assuming the proportion is 87.30%, 
and taking into account an expected dropout rate of 
20%, a minimum of 214 patients will be required.
Patient involvement
There was no patient or public involvement in the study 
design. The study aims to analyse regarding the time 
required by the patient to obtain the result, including the 
time of travel to the centre, the comfort of the test and 
opinions on recommending it to another patient.
Ethics and dissemination
The protocol presents a health technology trial to study 
a new test with a medical device, but is not a medicine. 
The procedures will follow Spanish and Catalan laws. 
Researchers will follow the ethical standards of the Decla-
ration of Helsinki for biomedical studies and the activ-
ities described will follow the Code of Good Practice in 
Clinical Research. The protocol has been authorised by 
the research ethics committee of the Hospital Clinic of 
Barcelona (Ref. HCB/2014/0615). Authorisation will be 
sought from the research ethics committee for protocol 
modifications, which will be reported to Clinical  Trials. 
gov. The results will be presented in the scientific litera-
ture, and to healthcare partners.
Confidentiality and data management
All study-related information will be stored securely at 
the study sites. All participant information will be stored 
in locked file cabinets in areas with limited access. Infor-
mation from participants will be identified by a coded 
identification number only to maintain participant 
confidentiality. All records that contain names or other 
personal identifiers, such as locator forms and informed 
consent forms, will be stored separately from study 
records identified by code number. All local databases 
will be secured with password-protected access systems.
Patient and public involvement
There was no patient or public involvement in the study 
design.
dIsCussIon
Hypertension is the most frequent reason for consultation 
in primary healthcare, representing nearly 6% of all visits 
to Spanish family physicians.22 The diagnosis of hyper-
tension depends on BP measurements. However, these 
vary widely, and include several hidden effects, including 
the white coat effect. Two of the most important interna-
tional guidelines suggest using 24-hour ABPM.4 6 Despite 
the validity and reliability of this method, it has draw-
backs: a high cost, the lack of instruments to carry out the 
procedure in all patients, the discomfort of the patient 
during sleep (the cuff activates every 30 min at night) and 
the reluctance of some patients to wear the device for 
24 hours.8 23 Therefore, in daily clinical practice, nurses 
and physicians use OBPM and HBPM which, while more 
feasible, lead to other problems such as overdiagnosis. 
1-BPM seems to have a sensitivity and specificity in the 
diagnosis of hypertension close to that obtained with 
daytime 24-hour ABPM and avoids the white coat effect 
and other BP effects. Another important aspect that 
will be examined in this study is the patient experience. 
In daily practice, clinicians use the best method in any 
tests requiring medical devices, despite the sensitivity 
and specificity values, as any diagnostic method requires 
examination of the patient experience to evaluate the 
global evidence.24
Limitations of the study
The validation of 1-BPM will not allow night-time 
recording of BP, a relevant issue in the assessment 
of cardiovascular risk. Nor does it seek to substitute 
24-hour ABPM. However, if the working hypothesis is veri-
fied, the new method will allow for a new valid, effective 
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diagnostic alternative, acceptable to the patient, and 
easily applicable in primary healthcare, and more reliable 
than HBPM and OBPM.
Author affiliations
1Les Corts Primary Health-Care Center, Consorci d’Atenció Primària de Salut 
Barcelona Esquerra, Barcelona, Spain
2Primary Healthcare Transversal Research Group, Institut d’Investigacions 
Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3Department of Statistics and Operational Research, Universitat Politècnica de 
Catalunya, Barcelona, Spain
4Compte Borrell Primary Health-Care Center, Consorci d’Atenció Primària de Salut 
Barcelona Esquerra, Barcelona, Spain
5Casanova Primary Health-Care Center, Consorci d’Atenció Primària de Salut 
Barcelona Esquerra, Barcelona, Spain
6Hypertension Unit, Servicio de Medicina Interna, Institut Clínic de Medicina Interna i 
Dermatologia (ICMID), Hospital Clínic de Barcelona, Barcelona, Spain
7Pharmacy Service, Hospital Clínic Barcelona, Barcelona, Spain
8Management office, Consorci d’Atenció Primària de Salut Barcelona Esquerra, 
Barcelona, Spain
Acknowledgements We thank all patients participating in the study.
Collaborators The OMBP group are: Monserrat Serrato, Ingrid Vidiella and Elisa 
Pérez (Les Corts Primary Health-Care Center); Eva Sanchez, María Ortega and Silvia 
Porcar (Compte Borrell Primary Health-Care Center); Xavier Freixa, Maica Herranz, 
Berta de Andrés and Elena Lagarda (Casanova Primary Health-Care Center).
Contributors LGP, BK and ASA are all involved in the conception and design of 
the study. LGP drafted the manuscript. LGP, BK and ASA revised the manuscript for 
important intellectual content and with MCAB, CC, NG, SR, EB, CSB, JMSM, JBA and 
ES read and approved the final manuscript.
Funding The project received a research grant from the Carlos III Institute of 
Health, Ministry of Economy and Competitiveness (Spain), awarded on the 2016 call 
under the Health Strategy Action 2013-2016, within the National Research Program 
oriented to Societal Challenges, within the Technical, Scientific and Innovation 
Research National Plan 2013-2016, with reference PI16/00660, co-funded 
with European Union ERDF funds (European Regional Development Fund). The 
funding source will play no role in the study design, data collection, analysis or 
interpretation, or the writing of the manuscript. The researchers retain complete 
independence in the conduct of the study. The evaluation committee will annually 
inspect study progress and adherence to the study protocol. Information can be 
viewed at at https:// bit. ly/ 2Q62fB. Study coordinators will report the results annually 
and the sponsor may audit the study completion and best practices.
Competing interests None declared.
Ethics approval Ethical approval was obtained from the Research Ethics 
Committee of the Hospital Clínic of Barcelona (Ref. number HCB/2014/0615). 
Written informed consent will be obtained from eligible participants before any 
assessment or intervention.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Banegas JR, Graciani A, de la Cruz-Troca JJ, et al. Achievement of 
cardiometabolic goals in aware hypertensive patients in Spain: a 
nationwide population-based study. Hypertension 2012;60:898–905.
 2. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular 
health metrics and associations with all-cause and CVD mortality 
among US adults. JAMA 2012;307:1273–83.
 3. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension 
Prevalence and Control: A Systematic Analysis of Population-Based 
Studies From 90 Countries. Circulation 2016;134:441–50.
 4. Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines 
for the management of arterial hypertension. Eur Heart J 
2018;2018:3021–104.
 5. Krause T, Lovibond K, Caulfield M, et al. Management of 
hypertension: summary of NICE guidance. BMJ 2011;343:d4891.
 6. Siu AL. U.S. Preventive Services Task Force. Screening for high 
blood pressure in adults: U.S. Preventive Services Task Force 
recommendation statement. Ann Intern Med 2015;163:778–86.
 7. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive 
accuracy of blood pressure screening methods with consideration 
of rescreening intervals: a systematic review for the U.S. Preventive 
Services Task Force. Ann Intern Med 2015;162:192–204.
 8. Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure 
monitoring in clinical practice: a review. Am J Med 2015;128:14–20.
 9. Stergiou GS, Parati G, Vlachopoulos C, et al. Methodology and 
technology for peripheral and central blood pressure and blood 
pressure variability measurement. J Hypertens 2016;34:1665–77.
 10. Mutlu S, Sari O, Arslan E, et al. Comparison of ambulatory 
blood pressure measurement with home, office and pharmacy 
measurements: is arterial blood pressure measured at pharmacy 
reliable? J Eval Clin Pract 2016;22:40–5.
 11. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between 
Clinic and Ambulatory Blood-Pressure Measurements and Mortality. 
N Engl J Med 2018;378:1509–20.
 12. Banegas JR, Segura J, Sobrino J, et al. Effectiveness of blood 
pressure control outside the medical setting. Hypertension 
2007;49:62–8.
 13. Little P, Barnett J, Barnsley L, et al. Comparison of agreement 
between different measures of blood pressure in primary care and 
daytime ambulatory blood pressure. BMJ 2002;325:254.
 14. Gaborieau V, Delarche N, Gosse P. Ambulatory blood pressure 
monitoring versus self-measurement of blood pressure at home: 
correlation with target organ damage. J Hypertens 2008;26:1919–27.
 15. Viera AJ, Hinderliter AL, Kshirsagar AV, et al. Reproducibility of 
masked hypertension in adults with untreated borderline office blood 
pressure: comparison of ambulatory and home monitoring. Am J 
Hypertens 2010;23:1190–7.
 16. Gorostidi M, Banegas JR, de la Sierra A, et al. Ambulatory blood 
pressure monitoring in daily clinical practice - the Spanish ABPM 
Registry experience. Eur J Clin Invest 2016;46:92–8.
 17. van der Wel MC, Buunk IE, van Weel C, et al. A novel approach 
to office blood pressure measurement: 30-minute office blood 
pressure vs daytime ambulatory blood pressure. Ann Fam Med 
2011;9:128–35.
 18. Mas-Heredia M, Molés-Moliner E, González-de Paz L, et al. Validity 
and applicability of a new recording method for hypertension. Rev 
Esp Cardiol 2014;67:717–23.
 19. Millaret M, Pons JMV. Participació de ciutadans i pacients en les 
polítiques de salut: conceptualització i experiències internacionals. 
1st ed. Generalitat de Catalunya. 2015. available in http:// aquas. 
gencat. cat/ web/. content/ minisite/ aquas/ publicacions/ 2015/ 
documents/ Participacio_ Ciutadans_ Pacients_ Informe_ AQuAS_ 2015. 
pdf (accessed 28 Mar 2019).
 20. Department of Health & Human Services. Premarket notification of 
intent to market the device Oscar 2. https://www. accessdata. fda. 
gov/ cdrh_ docs/ pdf15/ K151520. pdf.
 21. Oscar 2 - SunTech Medical. https://www. suntechmed. com/ bp- 
products/ ambulatory- blood- pressure- monitoring/ oscar- 2.
 22. Sicras-Mainar A, Navarro-Artieda R. [Cost of arterial hypertension 
according to levels of morbidity in primary care setting]. Med Clin 
2009;133:290–5.
 23. Chrubasik S, Droste C, Glimm E, et al. Comparison of different 
methods of blood pressure measurements. Blood Press Monit 
2007;12:157–66.
 24. World Health Organization. Regional Office for Europe. Exploring 
patient participation in reducing health-care related safety risks. 
Copenhagen, Denmark: WHO Regional Office for Europe. 2013. 
Available in http://www. euro. who. int/__ data/ assets/ pdf_ file/ 0010/ 
185779/ e96814. pdf (accessed 28 Mar 2019).
 o
n
 9 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029268 on 27 May 2019. Downloaded from 
